TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Open-label, Randomized Clinical Trial of Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX) Versus GEMOX Alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma
Brief Summary: This is a multi-centre phase II, open-label, randomized (1:1), parallel-arm, study of panitumumab in combination with chemotherapy (P-GEMOX) versus chemotherapy alone (GEMOX). Eligible subjects will be enrolled and randomized to receive first-line combination therapy consisting of panitumumab and GEMOX (experimental arm) or GEMOX alone (control arm).The ame of the Stuy is to evaluate the clinical activity of the P-GEMOX (Panitumumab and GEMOX) combination compared to GEMOX alone in patients with previously untreated surgically unresectable or metastatic biliary tract carcinoma (KRAS wild-type)and To evaluate the safety profile of the P-GEMOX combination; to assess the objective response rate; to assess overall survival; to study the correlation between biomarkers with activity and efficacy.


Options:
A: Arm Label: GEMOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine, oxaliplatin | Arm Label: E-GEMOX; Type: EXPERIMENTAL; Interventions: Drug: cetuximab, gemcitabine, oxaliplatin | Intervention Type: DRUG; Name: gemcitabine, oxaliplatin; Assigned to Arm(s): GEMOX | Intervention Type: DRUG; Name: cetuximab, gemcitabine, oxaliplatin; Assigned to Arm(s): E-GEMOX
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemox, Cetuximab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Gemox, Cetuximab | Intervention Type: DRUG; Name: Gemox, Cetuximab; Assigned to Arm(s): 1, 2
C: Arm Label: Arm A- p-Gemox; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab plus GEMOX chemotherapy, Drug: GEMOX chemotherapy | Arm Label: Arm B-GEMOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: GEMOX chemotherapy | Intervention Type: DRUG; Name: Panitumumab plus GEMOX chemotherapy; Assigned to Arm(s): Arm A- p-Gemox | Intervention Type: DRUG; Name: GEMOX chemotherapy; Assigned to Arm(s): Arm A- p-Gemox, Arm B-GEMOX
D: Arm Label: Arm NaI-IRI + 5-FU + Leucovorin (Arm A); Type: EXPERIMENTAL; Interventions: Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A) | Arm Label: Arm Cisplatin + Gemcitabine (Arm B, standard of care); Type: OTHER; Interventions: Drug: Arm Cisplatin + Gemcitabine (Arm B) | Intervention Type: DRUG; Name: Arm NaI-IRI + 5-FU + Leucovorin (Arm A); Assigned to Arm(s): Arm NaI-IRI + 5-FU + Leucovorin (Arm A) | Intervention Type: DRUG; Name: Arm Cisplatin + Gemcitabine (Arm B); Assigned to Arm(s): Arm Cisplatin + Gemcitabine (Arm B, standard of care)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 4 -16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES
Brief Summary: Study A0081041 is a double blind, placebo controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of two dose levels of pregabalin administered in equally divided daily doses, in either capsule or oral liquid formulation, as adjunctive therapy in pediatric subjects 4 to 16 years of age with partial onset seizures.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gabapentin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): B
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day, Brivaracetam 5 mg/day, Brivaracetam 50 mg/day
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 2.5 mg | Arm Label: BRV 20mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 10 mg | Arm Label: BRV 50mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam 25 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam 2.5 mg; Assigned to Arm(s): Brivaracetam 5 mg/day | Intervention Type: DRUG; Name: Brivaracetam 10 mg; Assigned to Arm(s): BRV 20mg/day | Intervention Type: DRUG; Name: Brivaracetam 25 mg; Assigned to Arm(s): BRV 50mg/day
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pregabalin add-on therapy | Arm Label: Pregabalin Level 1 (max 150 mg/day); Type: EXPERIMENTAL; Interventions: Drug: Pregabalin add-on therapy | Arm Label: Pregabalin Level 2 (max 600 mg day); Type: EXPERIMENTAL; Interventions: Drug: Pregabalin add-on therapy | Intervention Type: DRUG; Name: Pregabalin add-on therapy; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Pregabalin add-on therapy; Assigned to Arm(s): Pregabalin Level 1 (max 150 mg/day) | Intervention Type: DRUG; Name: Pregabalin add-on therapy; Assigned to Arm(s): Pregabalin Level 2 (max 600 mg day)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tailored Internet-administrated Treatment of Anxiety Disorders - A Randomised Controlled Trial (NOVA II)
Brief Summary: The purpose of this study is to determine whether tailored internet-administered cbt is a feasible treatment for anxiety disorders in clinical settings.


Options:
A: Arm Label: iSOFIE; Type: EXPERIMENTAL; Interventions: Other: iSOFIE | Arm Label: Waitlist control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: iSOFIE; Assigned to Arm(s): iSOFIE
B: Arm Label: tailored internet-administrated CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Internet-administrated CBT-Treatment | Arm Label: waitlist; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Waitlist | Intervention Type: BEHAVIORAL; Name: Tailored Internet-administrated CBT-Treatment; Assigned to Arm(s): tailored internet-administrated CBT | Intervention Type: BEHAVIORAL; Name: Waitlist; Assigned to Arm(s): waitlist
C: Arm Label: Internet-based CBT; Type: N/A; Interventions: N/A
D: Arm Label: Smartphone-supplemented iCBT with therapist support; Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone-supplemented iCBT, Behavioral: Therapist support | Arm Label: Smartphone-supplemented iCBT without therapist support; Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone-supplemented iCBT | Arm Label: Active waiting list control group with delayed treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smartphone-supplemented iCBT, Other: Active waiting list | Intervention Type: BEHAVIORAL; Name: Smartphone-supplemented iCBT; Assigned to Arm(s): Active waiting list control group with delayed treatment, Smartphone-supplemented iCBT with therapist support, Smartphone-supplemented iCBT without therapist support | Intervention Type: BEHAVIORAL; Name: Therapist support; Assigned to Arm(s): Smartphone-supplemented iCBT with therapist support | Intervention Type: OTHER; Name: Active waiting list; Assigned to Arm(s): Active waiting list control group with delayed treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tailored Internet-administrated Treatment of Anxiety Disorders - A Randomised Controlled Trial (NOVA II)
Brief Summary: The purpose of this study is to determine whether tailored internet-administered cbt is a feasible treatment for anxiety disorders in clinical settings.


Options:
A: Arm Label: Tailored Internet-delivered CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Internet-administrated CBT-Treatment | Arm Label: Waitlist; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Waitlist | Intervention Type: BEHAVIORAL; Name: Tailored Internet-administrated CBT-Treatment; Assigned to Arm(s): Tailored Internet-delivered CBT | Intervention Type: BEHAVIORAL; Name: Waitlist; Assigned to Arm(s): Waitlist
B: Arm Label: Internet CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based cognitive behavior therapy (CBT). | Arm Label: Group CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Group CBT | Intervention Type: BEHAVIORAL; Name: Internet-based cognitive behavior therapy (CBT).; Assigned to Arm(s): Internet CBT | Intervention Type: BEHAVIORAL; Name: Group CBT; Assigned to Arm(s): Group CBT
C: Arm Label: tailored internet-administrated CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Internet-administrated CBT-Treatment | Arm Label: waitlist; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Waitlist | Intervention Type: BEHAVIORAL; Name: Tailored Internet-administrated CBT-Treatment; Assigned to Arm(s): tailored internet-administrated CBT | Intervention Type: BEHAVIORAL; Name: Waitlist; Assigned to Arm(s): waitlist
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-delivered CBT. | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: On line discussion group | Intervention Type: BEHAVIORAL; Name: Internet-delivered CBT.; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: On line discussion group; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adolescent Immunization Recall Systems: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether contacting the parents of adolescents overdue for routine vaccines or contacting both the parents AND adolescents overdue to routine vaccines improves immunization rates as compared to usual care.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Parent Only Group; Type: EXPERIMENTAL; Interventions: Other: Parent Only Phone Call | Arm Label: Parent and Adolescent Group; Type: EXPERIMENTAL; Interventions: Other: Parent and Adolescent Phone Call | Intervention Type: OTHER; Name: Parent Only Phone Call; Assigned to Arm(s): Parent Only Group | Intervention Type: OTHER; Name: Parent and Adolescent Phone Call; Assigned to Arm(s): Parent and Adolescent Group
B: Arm Label: mailed reminder notice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mailed influenza vaccination reminder notice | Arm Label: No reminder notice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mailed influenza vaccination reminder notice; Assigned to Arm(s): mailed reminder notice
C: Arm Label: SMS Vaccine; Type: N/A; Interventions: Behavioral: SMS message reminding mothers to come for their scheduled vaccines | Arm Label: Usual care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS message reminding mothers to come for their scheduled vaccines; Assigned to Arm(s): SMS Vaccine
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Device: "COMBINED STRATEGY" | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: "COMBINED STRATEGY"; Assigned to Arm(s): Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Multicenter, Open-label, Active-Controlled, Phase 2 Study of LY2510924 and Sunitinib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Brief Summary: To compare the progression free survival of LY2510924 plus sunitinib therapy versus sunitinib in the first-line setting for patients with metastatic clear-cell renal cell carcinoma.


Options:
A: Arm Label: Arm A (sunitinib malate, placebo); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment, Drug: Sunitinib Malate | Arm Label: Arm B (sorafenib tosylate, placebo); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment, Drug: Sorafenib Tosylate | Arm Label: Arm C (placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (sunitinib malate, placebo), Arm B (sorafenib tosylate, placebo), Arm C (placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm A (sunitinib malate, placebo), Arm B (sorafenib tosylate, placebo), Arm C (placebo) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm A (sunitinib malate, placebo), Arm B (sorafenib tosylate, placebo), Arm C (placebo) | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm B (sorafenib tosylate, placebo) | Intervention Type: DRUG; Name: Sunitinib Malate; Assigned to Arm(s): Arm A (sunitinib malate, placebo)
B: Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tarceva (erlotinib HCl); Assigned to Arm(s): N/A
C: Arm Label: LY2510924 + Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: LY2510924, Drug: Sunitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: LY2510924; Assigned to Arm(s): LY2510924 + Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): LY2510924 + Sunitinib, Sunitinib
D: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Multicenter, Open-label, Active-Controlled, Phase 2 Study of LY2510924 and Sunitinib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Brief Summary: To compare the progression free survival of LY2510924 plus sunitinib therapy versus sunitinib in the first-line setting for patients with metastatic clear-cell renal cell carcinoma.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Drug: Bevacizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon alpha-2a | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon alpha-2a; Assigned to Arm(s): C
B: Arm Label: LY2510924 + Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: LY2510924, Drug: Sunitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: LY2510924; Assigned to Arm(s): LY2510924 + Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): LY2510924 + Sunitinib, Sunitinib
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Axitinib (AG-013736) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): B
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Beneficial Effect of Probiotics on Chronic Kidney Disease
Brief Summary: This is a randomized double blinded placebo control studies are performed in Chronic Kidney Disease (CKD) patients. After informed consent, intervention group receives probiotics containing 109 CFU B. bifidum, B.catenulatum, B. longum, and L.plantarm), while placebo group receives corn starch. In the first year the investigators examine the 60 peritoneal dialysis (PD) patients, in the second year the investigators do the 60 hemodialysis (HD) patients, and in the third year the investigators do the 60 stage 3 and 4 CKD patients. Primary endpoint is cardiovascular event, gastrointestinal symptoms, peritonitis in PD patients, and progression of stage 3 and 4 CKD. Values are compared between the groups by unpaired t test. X2 testis used to compare proportions between the groups. Relative risk and the number needed to treat, both with 95% CI, are used to describe the treatment effect of probiotics. A p value less than 0•05 is regarded as statistically significant.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cornstarch | Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Cornstarch; Assigned to Arm(s): Placebo
B: Arm Label: Fructooligosaccharide; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fructooligosaccharide | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Fructooligosaccharide; Assigned to Arm(s): Fructooligosaccharide | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
C: Arm Label: SYNBIOTIC; Type: EXPERIMENTAL; Interventions: Dietary Supplement: SYNBIOTIC | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: SYNBIOTIC; Assigned to Arm(s): SYNBIOTIC
D: Arm Label: Probiotics; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Probiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Placebo, Probiotics

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Dihydroartemisinin-piperaquine With or Without Primaquine on Gametocytes Plasmodium Falciparum in Mesoendemic Area of Indonesia
Brief Summary: Artemisinin-based combination therapy (ACT) has been known to be controversial for stopping malaria transmission.The addition of primaquine (PQ) - the only drug commercially available that kills mature transmission stage - to such treatments might be necessary to eliminate this stage. A study is conducted to evaluate the efficacy of dihydroartemisinin-piperaquine (DHP) regimens with or without PQ on the sexual and asexual stages of P. falciparum in Sumatra, Indonesia.


Options:
A: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: chlorproguanil-dapsone-artesunate, Drug: chlorproguanil-dapsone | Intervention Type: DRUG; Name: chlorproguanil-dapsone-artesunate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): Arm 1
C: Arm Label: artemether-lumefantrine+placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo (For artemether-lumefantrine arm) | Arm Label: artemether-lumefantrine+primaquine; Type: EXPERIMENTAL; Interventions: Drug: Primaquine (For artemether-lumefantrine+primaquine arm) | Intervention Type: DRUG; Name: Primaquine (For artemether-lumefantrine+primaquine arm); Assigned to Arm(s): artemether-lumefantrine+primaquine | Intervention Type: DRUG; Name: Placebo (For artemether-lumefantrine arm); Assigned to Arm(s): artemether-lumefantrine+placebo
D: Arm Label: dihydroartemisinin-piperaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine | Arm Label: Dihydroartemisininpiperaquine primaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine + primaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine; Assigned to Arm(s): dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine + primaquine; Assigned to Arm(s): Dihydroartemisininpiperaquine primaquine

Answer: D